Table 1.
Neuraminidase inhibitors currently approved or undergoing clinical trials for treatment and prophylaxis against influenza.
| Drug | Code name | Chemical name | Brand name | Company | Route | Approval year | Reference1 |
|---|---|---|---|---|---|---|---|
| Oseltamivir | GS4104 | ethyl (3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylate;phosphoric acid | Tamiflu® | Roche | Oral | 1999 | Kim et al., 1997 |
| Zanamivir | 139110-80-8 | (2R,3R,4S)-3-acetamido-4-(guanidino)-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid | Relenza® | GlaxoSmithKline | Oral inhalation | 1999 | von Itzstein et al., 1993 |
| Peramivir | BCX-1812 and RWJ-270201 | (1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid | Rapivab® | BioCryst | Intravenous | 2014 | Babu et al., 2000 |
| Laninamivir | R-125489 | (2R,3R,4S)-3-acetamido-4-(guanidino)-2-[(1R,2R)-2,3-dihydroxy-1-methoxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid | Inavir® | Daiichi Sankyo/Biota | Oral inhalation | -2 | Yamashita et al., 2009 |
1Details on nomenclature and structure can be found at https://pubchem.ncbi.nlm.nih.gov
2Laninamivir was granted approval for clinical use in Japan in 2010 and is currently used in clinical practice.